PDF herunterladen
Planta Med 2023; 89(10): 964-978
DOI: 10.1055/a-2058-3863
Biological and Pharmacological Activity
Original Papers

Bio-evaluation of Untapped Alkaloids from Vinca minor Enriched by Methyl-jasmonate-induced Stress: an Integrated Approach

Fardous F. El-Senduny
1   Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt
2   Department of Pathology & Laboratory Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United States
,
Abdullah A. Elgazar 
3   Department of Pharmacognosy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt
,
Heba Allah Alwasify
4   Zoology Department, Faculty of Science, Mansoura University, Mansoura, Egypt
,
Alaa Abed
1   Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt
,
Mohamed Foda
1   Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt
,
Sara Abouzeid
5   Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
6   Institute for Plant Biology, Technische Universität Braunschweig, Braunschweig, Germany
,
Laura Lewerenz
6   Institute for Plant Biology, Technische Universität Braunschweig, Braunschweig, Germany
,
Dirk Selmar   *
6   Institute for Plant Biology, Technische Universität Braunschweig, Braunschweig, Germany
,
Farid Badria   *
5   Pharmacognosy Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
› InstitutsangabenGefördert durch: Science and Technology Development Fund 33601
› Weitere Informationen
    Lizenzen und Reprints

Abstract

The low amount of metabolites isolated from natural products is one of the challenges preventing their biological evaluation. The modulation of biosynthetic pathways by stimulating stress-induced responses in plants was proven to be a valuable tool for diversification of already known natural products. Recently, we reported the dramatic effect of methyl jasmonate (MeJA) on Vinca minor alkaloids distribution. In this study, three compounds identified as 9-methoxyvincamine, minovincinine, and minovincine are successfully isolated in good yield and subjected to several bioassays based on a network pharmacology study. The extracts and isolated compounds show weak to moderate antimicrobial and cytotoxic activities. Also, they are found to significantly promote wound healing in scratch assay, and transforming growth factor-β (TGF-β) modulation is suggested to be the potential pathway based on bioinformatic analysis. Hence, Western blotting is used to assess the expression of several markers related to this pathway and wound healing. The extracts and isolated compounds are able to increase the expression of Smad3 and Phosphatidylinositol-3-kinase (PI3K), while downregulating the levels of cyclin D1 and the mammalian target of rapamycin (mTOR) except for minovincine, which increases the mTOR expression, inferring that it might act through a different mechanism. Molecular docking is used to give insights on the ability of isolated compounds to bind with different active sites in mTOR. Collectively, the integrated phytochemical, in silico, and molecular biology approach reveal that V. minor and its metabolite could be repurposed for the management of dermatological disorders where these markers are dysregulated, which opens the gate to develop new therapeutics in the future.

Key words

Vinca minor - Apocynaceae - vinca alkaloids - chemical elicitor - in silico pharmacology - wound healing

* Corresponding authors


Supporting Information

    HPLC conditions, chromatograms, list of used antibodies for Western blot study, network pharmacology data, and antimicrobial disc diffusion assay figures are available as supporting information.

  • Ergänzendes Material


Publikationsverlauf

Eingereicht: 17. Dezember 2022

Angenommen nach Revision: 20. März 2023

Accepted Manuscript online:
20. März 2023

Artikel online veröffentlicht:
15. Mai 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Proksa B, Grossmann E. High performance liquid chromatographic determination of alkaloids from Vinca minor L. Phytochem Anal 1991; 2: 74-76
    CrossrefPubMedGoogle Scholar
  • 2 Kittakoop P, Mahidol C, Ruchirawat S. Alkaloids as important scaffolds in therapeutic drugs for the treatments of cancer, tuberculosis, and smoking cessation. Curr Top Med Chem 2014; 14: 239-252
    CrossrefPubMedGoogle Scholar
  • 3 Lounasmaa M, Tolvanen A. Chapter 1 Eburnamine–Vincamine Alkaloids. In: Cordell GA. ed. The Alkaloids: Chemistry and Pharmacology. Chicago: Academic Press; 1992. 42. 1-116
    Google Scholar
  • 4 Abouzeid S, Beutling U, Surup F, Abdel Bar FM, Amer MM, Badria FA, Yahyazadeh M, Brönstrup M, Selmar D. Treatment of Vinca minor Leaves with methyl jasmonate extensively alters the pattern and composition of indole alkaloids. J Nat Prod 2017; 80: 2905-2909
    CrossrefPubMedGoogle Scholar
  • 5 Abouzeid SAA. Modulation of indole alkaloid composition in Vinca minor [Dissertation]. Braunschweig: Technische Universität Braunschweig; 2018
    Google Scholar
  • 6 Abouzeid S, Beutling U, Selmar D. Stress-induced modification of indole alkaloids: Phytomodificines as a new category of specialized metabolites. Phytochemistry 2019; 159: 102-107
    CrossrefPubMedGoogle Scholar
  • 7 Jha M, Rahman M, Sheikh H. Vinpocetine: A smart drug and a smart nutrient: A review. Int J Pharm Sci Res 2012; 3: 346
    PubMedGoogle Scholar
  • 8 Baillie GS, Tejeda GS, Kelly MP. Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: Inhibition and beyond. Nat Rev Drug Discov 2019; 18: 770-796
    CrossrefPubMedGoogle Scholar
  • 9 Badria FA, Elgazar AA. Chapter 37 – Revealing the molecular mechanism of Olea europaea L. in treatment of cataract. In: Preedy VR, Watson RR. eds. Olives and Olive Oil in Health and Disease Prevention (Second Edition). San Diego: Academic Press; 2021: 445-456
    Google Scholar
  • 10 Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-690
    CrossrefPubMedGoogle Scholar
  • 11 Kiss B, Kárpáti E. [Mechanism of action of vinpocetine]. Acta Pharm Hung 1996; 66: 213-224
    PubMedGoogle Scholar
  • 12 Zhang YS, Li JD, Yan C. An update on vinpocetine: New discoveries and clinical implications. Eur J Pharmacol 2018; 819: 30-34
    CrossrefPubMedGoogle Scholar
  • 13 Zhang ZY, Dong SM, Liu YH, Zhang MM, Zhang JK, Zhu HJ, Shao JA, Liu HQ, Li YL, Zhang C, Zeng LH. Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3β signaling axis in hepatocellular carcinoma cells. Anti-Cancer Drugs 2021; 32
    PubMedGoogle Scholar
  • 14 Kim JS, Yu IH, Joo JH, Nam GH, Jung KH, Chung YS, Lee H. Biological effects of Vinca minor extract; Tyrosinase inhibition, stimulation of ROS generation and increasement of cell migration activity in keratinocytes. J Korean Appl Sci Technol 2016; 33: 788-794
    PubMedGoogle Scholar
  • 15 Barakat W, Anwar H, Mahmoud MJ. Sildenafil and Vinpocetine Promote Wound Healing in Diabetic Rats. JAPR 2021; 5: 211-221
    PubMedGoogle Scholar
  • 16 Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res 2010; 89: 219-229
    CrossrefPubMedGoogle Scholar
  • 17 Pradhan L, Nabzdyk C, Andersen ND, LoGerfo FW, Veves A. Inflammation and neuropeptides: The connection in diabetic wound healing. Expert Rev Mol Med 2009; 11: e2
    CrossrefPubMedGoogle Scholar
  • 18 Hsu YC, Hsiao M, Chien YW, Lee WR. Exogenous nitric oxide stimulated collagen type I expression and TGF-β1 production in keloid fibroblasts by a cGMP-dependent manner. Nitric Oxide 2007; 16: 258-265
    CrossrefPubMedGoogle Scholar
  • 19 Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986; 83: 4167-4171
    CrossrefPubMedGoogle Scholar
  • 20 Pastar I, Stojadinovic O, Yin NC, Ramirez H, Nusbaum AG, Sawaya A, Patel SB, Khalid L, Isseroff RR, Tomic-Canic M. Epithelialization in wound healing: A comprehensive review. Adv Wound Care (New Rochelle) 2014; 3: 445-464
    CrossrefPubMedGoogle Scholar
  • 21 Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-b/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001; 276: 17058-17062
    CrossrefPubMedGoogle Scholar
  • 22 Kim SA, Ryu YW, Kwon JI, Choe MS, Jung JW, Cho JW. Differential expression of cyclin D1, Ki-67, pRb, and p 53 in psoriatic skin lesions and normal skin. Mol Med Rep 2018; 17: 735-742
    PubMedGoogle Scholar
  • 23 Pagano M, Theodoras AM, Tam SW, Draetta GF. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 1994; 8: 1627-1639
    CrossrefPubMedGoogle Scholar
  • 24 Fogel AL, Hill S, Teng JMC. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology. J Am Acad Dermatol 2015; 72: 879-889
    CrossrefPubMedGoogle Scholar
  • 25 Ong CT, Khoo YT, Mukhopadhyay A, Do DV, Lim IJ, Aalami O, Phan TT. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol 2007; 16: 394-404
    CrossrefPubMedGoogle Scholar
  • 26 Woo J, Shin S, Ji H, Ryu D, Cho E, Kim Y, Kim J, Park D, Jung E. Isatis tinctoria L. Leaf Extract Inhibits Replicative Senescence in Dermal Fibroblasts by Regulating mTOR-NF-κB-SASP Signaling. Nutrients 2022; 14: 1979
    CrossrefPubMedGoogle Scholar
  • 27 Moon J, Lee SY, Choi JW, Lee AR, Yoo JH, Moon SJ, Park SH, Cho ML. Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts. J Transl Med 2021; 19: 192
    CrossrefPubMedGoogle Scholar
  • 28 Lawrence J, Nho R. The role of the mammalian Target of Rapamycin (mTOR) in pulmonary fibrosis. Int J Mol Sci 2018; 19: 778
    CrossrefPubMedGoogle Scholar
  • 29 Jere SW, Houreld NN, Abrahamse H. Role of the PI3K/AKT (mTOR and GSK3β) signalling pathway and photobiomodulation in diabetic wound healing. Cytokine Growth Factor Rev 2019; 50: 52-59
    CrossrefPubMedGoogle Scholar
  • 30 Doi T, Obayashi K, Kadowaki T, Fujii H, Koyasu S. PI3K is a negative regulator of IgE production. Int Immunol 2008; 20: 499-508
    CrossrefPubMedGoogle Scholar
  • 31 Kang HS, Song JY, Kim JH, Il Park T, Choi WS, Lee JY. Effects of vinpocetine on atopic dermatitis after administration via three different routes in HR-1 hairless mice. Pharmazie 2022; 77: 9-13
    PubMedGoogle Scholar
  • 32 Li Y, Zou Q, Zhang J. Vincamine exerts protective effect on spiral ganglion neurons in endolymphatic hydrops guinea pig models. Am J Transl Res 2018; 10: 3650-3663
    PubMedGoogle Scholar
  • 33 Yang H, Chen X, Liu M, Xu Y. The structure of mTOR complexes at a glance. PCM 2018; 1: 7
    PubMedGoogle Scholar
  • 34 Sapam TD, Velmurugan Ilavarasi A, Palaka BK, Elumalai E, Kanika ND, Ampasala DR. Identifying novel small molecule antagonists for mLST8 protein using computational approaches. J Recept Signal Transduct Res 2018; 38: 1-11
    CrossrefPubMedGoogle Scholar
  • 35 Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature 2013; 497: 217-223
    CrossrefPubMedGoogle Scholar
  • 36 Scaiola A, Mangia F, Imseng S, Boehringer D, Berneiser K, Shimobayashi M, Stuttfeld E, Hall MN, Ban N, Maier T. The 3.2-Å resolution structure of human mTORC2. Sci Adv 2020; 6: eabc1251
    CrossrefPubMedGoogle Scholar
  • 37 Murugan AK, Alzahrani A, Xing M. Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem 2013; 288: 6511-6521
    CrossrefPubMedGoogle Scholar
  • 38 Feng YQ, Gu SX, Chen YS, Gao XD, Ren YX, Chen JC, Lu YY, Zhang H, Cao S. Virtual screening and optimization of novel mTOR inhibitors for radiosensitization of hepatocellular carcinoma. Drug Des Devel Ther 2020; 14: 1779-1798
    CrossrefPubMedGoogle Scholar
  • 39 Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS. Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1, 6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian Target of Rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem 2011; 54: 1473-1480
    CrossrefPubMedGoogle Scholar
  • 40 Liu X, Ouyang S, Yu B, Liu Y, Huang K, Gong J, Zheng S, Li Z, Li H, Jiang H. PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res 2010; 38: W609-614
    CrossrefPubMedGoogle Scholar
  • 41 Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7: 42717
    CrossrefPubMedGoogle Scholar
  • 42 Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017; 45: D362-D368
    CrossrefPubMedGoogle Scholar
  • 43 Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 2022; 50: W216-W221
    CrossrefPubMedGoogle Scholar
  • 44 El-Senduny FF, Shabana SM, Rosel D, Brabek J, Althagafi I, Angeloni G, Manolikakes G, Shaaban S. Urea-functionalized organoselenium compounds as promising anti-HepG2 and apoptosis-inducing agents. Future Med Chem 2021; 13: 1655-1677
    CrossrefPubMedGoogle Scholar
  • 45 Liu Y, Yang X, Gan J, Chen S, Xiao ZX, Cao Y. CB-Dock2: Improved protein–ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res 2022; 50: W159-W164
    CrossrefPubMedGoogle Scholar